Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.
Stock Performance
Silo Pharma News 81 articles
- Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
- Silo Pharma regains compliance with Nasdaq minimum bid price requirement
- Silo Pharma welcomes federal psychedelic actions, touts SPC-15 PTSD candidate
- Silo Pharma updates SPC-15 PTSD program and adds digital-asset treasury strategy
- Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
- Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
- Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
- Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
- Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
- Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
- Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
- Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
- Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
- Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
- Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
- Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
- Silo Pharma Secures Exclusive Global License for Alzheimer’s Therapeutic
- Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
- Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
- Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
- Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
- Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
- Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
- Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
- Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
- Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
- Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
- Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
- Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
- Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
- Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
- Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
- Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
- Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
- Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
- Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
- Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
- Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
Showing the 40 most recent of 81 articles.